404 related articles for article (PubMed ID: 29959213)
1. Combined VLA-4-Targeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma.
Choi J; Beaino W; Fecek RJ; Fabian KPL; Laymon CM; Kurland BF; Storkus WJ; Anderson CJ
J Nucl Med; 2018 Dec; 59(12):1843-1849. PubMed ID: 29959213
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of (68)Ga- and (177)Lu-DOTA-PEG4-LLP2A for VLA-4-Targeted PET Imaging and Treatment of Metastatic Melanoma.
Beaino W; Nedrow JR; Anderson CJ
Mol Pharm; 2015 Jun; 12(6):1929-38. PubMed ID: 25919487
[TBL] [Abstract][Full Text] [Related]
3. PET imaging of very late antigen-4 in melanoma: comparison of 68Ga- and 64Cu-labeled NODAGA and CB-TE1A1P-LLP2A conjugates.
Beaino W; Anderson CJ
J Nucl Med; 2014 Nov; 55(11):1856-63. PubMed ID: 25256059
[TBL] [Abstract][Full Text] [Related]
4. Albumin-Binding Lutetium-177-Labeled LLP2A Derivatives as Theranostics for Melanoma.
Pun MD; Gallazzi F; Ho KV; Watkinson L; Carmack TL; Iweha E; Li L; Anderson CJ
Mol Pharm; 2024 Jun; 21(6):2960-2969. PubMed ID: 38680059
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Al
Gai Y; Yuan L; Sun L; Li H; Li M; Fang H; Altine B; Liu Q; Zhang Y; Zeng D; Lan X
J Biol Inorg Chem; 2020 Feb; 25(1):99-108. PubMed ID: 31745667
[TBL] [Abstract][Full Text] [Related]
6. Ex Vivo and In Vivo Evaluation of Overexpressed VLA-4 in Multiple Myeloma Using LLP2A Imaging Agents.
Soodgupta D; Zhou H; Beaino W; Lu L; Rettig M; Snee M; Skeath J; DiPersio JF; Akers WJ; Laforest R; Anderson CJ; Tomasson MH; Shokeen M
J Nucl Med; 2016 Apr; 57(4):640-5. PubMed ID: 26742713
[TBL] [Abstract][Full Text] [Related]
7. Molecular imaging of very late antigen-4 (α4β1 integrin) in the premetastatic niche.
Shokeen M; Zheleznyak A; Wilson JM; Jiang M; Liu R; Ferdani R; Lam KS; Schwarz JK; Anderson CJ
J Nucl Med; 2012 May; 53(5):779-86. PubMed ID: 22496586
[TBL] [Abstract][Full Text] [Related]
8. PET Imaging of VLA-4 in a New BRAF
Bellavia MC; Nyiranshuti L; Latoche JD; Ho KV; Fecek RJ; Taylor JL; Day KE; Nigam S; Pun M; Gallazzi F; Edinger RS; Storkus WJ; Patel RB; Anderson CJ
Mol Imaging Biol; 2022 Jun; 24(3):425-433. PubMed ID: 34694528
[TBL] [Abstract][Full Text] [Related]
9. A Metal-Free DOTA-Conjugated
Roxin Á; Zhang C; Huh S; Lepage M; Zhang Z; Lin KS; Bénard F; Perrin DM
Bioconjug Chem; 2019 Apr; 30(4):1210-1219. PubMed ID: 30896929
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of [
Cortez A; Josefsson A; McCarty G; Shtekler AE; Rao A; Austin Z; Nedrow JR
Nucl Med Biol; 2020; 88-89():62-72. PubMed ID: 32799049
[TBL] [Abstract][Full Text] [Related]
11. Preliminary evaluation of
Roxin Á; Zhang C; Huh S; Lepage ML; Zhang Z; Lin KS; Bénard F; Perrin DM
Nucl Med Biol; 2018 Jun; 61():11-20. PubMed ID: 29597141
[TBL] [Abstract][Full Text] [Related]
12. Comparison of two cross-bridged macrocyclic chelators for the evaluation of 64Cu-labeled-LLP2A, a peptidomimetic ligand targeting VLA-4-positive tumors.
Jiang M; Ferdani R; Shokeen M; Anderson CJ
Nucl Med Biol; 2013 Feb; 40(2):245-51. PubMed ID: 23265977
[TBL] [Abstract][Full Text] [Related]
13. Targeted systemic radiotherapy with scVEGF/177Lu leads to sustained disruption of the tumor vasculature and intratumoral apoptosis.
Blankenberg FG; Levashova Z; Goris MG; Hamby CV; Backer MV; Backer JM
J Nucl Med; 2011 Oct; 52(10):1630-7. PubMed ID: 21890879
[TBL] [Abstract][Full Text] [Related]
14. Integrin α
Chen H; Zhao L; Fu K; Lin Q; Wen X; Jacobson O; Sun L; Wu H; Zhang X; Guo Z; Lin Q; Chen X
Theranostics; 2019; 9(25):7948-7960. PubMed ID: 31695808
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and Evaluation of New Bifunctional Chelators with Phosphonic Acid Arms for Gallium-68 Based PET Imaging in Melanoma.
Gai Y; Sun L; Lan X; Zeng D; Xiang G; Ma X
Bioconjug Chem; 2018 Oct; 29(10):3483-3494. PubMed ID: 30205001
[TBL] [Abstract][Full Text] [Related]
16. PET imaging facilitates antibody screening for synergistic radioimmunotherapy with a
Ren J; Xu M; Chen J; Ding J; Wang P; Huo L; Li F; Liu Z
Theranostics; 2021; 11(1):304-315. PubMed ID: 33391476
[No Abstract] [Full Text] [Related]
17. Immune checkpoint inhibitors reverse tolerogenic mechanisms induced by melanoma targeted radionuclide therapy.
Rouanet J; Benboubker V; Akil H; Hennino A; Auzeloux P; Besse S; Pereira B; Delorme S; Mansard S; D'Incan M; Degoul F; Rouzaire PO
Cancer Immunol Immunother; 2020 Oct; 69(10):2075-2088. PubMed ID: 32447411
[TBL] [Abstract][Full Text] [Related]
18. Temporal analysis of type 1 interferon activation in tumor cells following external beam radiotherapy or targeted radionuclide therapy.
Jagodinsky JC; Jin WJ; Bates AM; Hernandez R; Grudzinski JJ; Marsh IR; Chakravarty I; Arthur IS; Zangl LM; Brown RJ; Nystuen EJ; Emma SE; Kerr C; Carlson PM; Sriramaneni RN; Engle JW; Aluicio-Sarduy E; Barnhart TE; Le T; Kim K; Bednarz BP; Weichert JP; Patel RB; Morris ZS
Theranostics; 2021; 11(13):6120-6137. PubMed ID: 33995649
[No Abstract] [Full Text] [Related]
19. Antitumor efficacy of
Potluri HK; Ferreira CA; Grudzinski J; Massey C; Aluicio-Sarduy E; Engle JW; Kwon O; Marsh IR; Bednarz BP; Hernandez R; Weichert JP; McNeel DG
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 36002185
[TBL] [Abstract][Full Text] [Related]
20. Targeted antisense radiotherapy and dose fractionation using a (177)Lu-labeled anti-bcl-2 peptide nucleic acid-peptide conjugate.
Liu D; Balkin ER; Jia F; Ruthengael VC; Smith CJ; Lewis MR
Nucl Med Biol; 2015 Sep; 42(9):704-10. PubMed ID: 26081917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
